CTMXHIGH SIGNALFINANCIAL10-K

CTMX experienced a dramatic financial turnaround with stockholders' equity swinging from negative $456K to positive $99M while operating performance deteriorated significantly with revenue declining 45% and the company returning to substantial losses.

The massive equity improvement suggests a major financing event or debt restructuring that resolved the company's negative equity position, but this came alongside a severe deterioration in operating fundamentals. The sharp decline in revenue and return to significant losses indicates potential setbacks in their clinical programs or partnerships, creating uncertainty about the sustainability of their improved balance sheet position.

Comparing 2026-03-16 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

CTMX underwent a dramatic financial transformation with stockholders' equity surging over 21,000% from deeply negative territory to $99M, likely from equity financing that also enabled a 57% reduction in total liabilities. However, operating performance collapsed with revenue falling 45% to $76M and the company swinging from $32M profit to $17M loss, suggesting significant business headwinds. Despite cash declining 67% to $13M, current assets grew 34% overall, but the combination of deteriorating operations and reduced cash runway presents liquidity concerns going forward.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+21812.3%
-$456K$99.0M

Equity base grew 21812.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Income
P&L
-189.5%
$25.0M-$22.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Net Income
P&L
-154.5%
$31.9M-$17.4M

Net income declined 154.5% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-66.7%
$38.1M$12.7M

Cash declined 66.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
-56.6%
$121.0M$52.6M

Liabilities reduced 56.6% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-45.7%
$85.8M$46.6M

Current liabilities reduced — improved short-term financial position and working capital health.

Revenue
P&L
-44.8%
$138.1M$76.2M

Revenue declined 44.8% — significant demand weakness or market share loss warrants investigation.

Accounts Receivable
Balance Sheet
-35.1%
$3.1M$2.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Assets
Balance Sheet
+34.1%
$107.3M$143.9M

Current assets grew 34.1% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-29%
$310K$220K

Capex reduced 29% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-06
ADDED
As of February 28, 2026, 170,186,742 sha res of the registrant s common stock, $0.00001 par value per share, were outstanding.
If we do not achieve our projected development and commercialization goals in the time frames we announce and expect, the commercialization of any of our product candidates may be delayed, or never attained, and our business will be harmed.
Business Overview We are a clinical-stage, oncology-focused biopharmaceutical company dedicated to developing innovative therapies to address major unmet need in oncology.
CytomX has led the field of conditionally activated, masked biologics through the development of its PROBODY technology platform.
This versatile, multi-modality platform is built on a strong foundation of tumor biology expertise, including deep knowledge of tumor-associated enzymes known as proteases.
+7 more — sign up free →
REMOVED
As of February 28 , 2025, 80,099,889 sha res of the registrant s common stock, $0.00001 par value per share, were outstanding.
This number does not include 6,923,077 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of February 28, 2025 (which are immediately exercisable at an exercise price of $0.00001 per share of common stock, subject to beneficial ownership limitations) sold in the registrant s private placement in July 2023.
See Note 12 Common Stock to the registrant s audited financial statements.
If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect the commercialization of any of our product candidates may be delayed, or never attained, and our business will be harmed.
Business Overview We are a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →